Literature DB >> 6449280

Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy.

C H Nash, S E Jones, T E Moon, S L Davis, S E Salmon.   

Abstract

Univariate and multivariate regression methods were used to analyze 17 potential clinical prognostic factors among 138 patients with advanced breast cancer who received Adriamycin-cyclophosphamide combination chemotherapy between 1973 and 1977 at the University of Arizona. Follow-up of patients was through September 1979, and survival data were nearly complete. Different factors varied in the relationship to outcome, but age, treatment, and response were important. Selecting the three most strongly related factors, predictive regression equations were developed, which described three types of possible outcome: 1) objective response (age, treatment, and liver involvement), 2) freedom from relapse (age, lung involvement, and response), and 3) survival (age, the number of involved sites [less than or equal to 2 or > 2], and treatment). Since use of the regression equations is cumbersome for clinical practice, three simplified tables were constructed to readily predict response, duration of response, and survival before the initiation of treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6449280     DOI: 10.1002/1097-0142(19801201)46:11<2380::aid-cncr2820461113>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Authors:  Reva K Basho; Clinton Yam; Michael Gilcrease; Rashmi K Murthy; Thorunn Helgason; Daniel D Karp; Funda Meric-Bernstam; Kenneth R Hess; Vicente Valero; Constance Albarracin; Jennifer K Litton; Mariana Chavez-MacGregor; David Hong; Razelle Kurzrock; Gabriel N Hortobagyi; Filip Janku; Stacy L Moulder
Journal:  Oncologist       Date:  2018-08-23

Review 2.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.

Authors:  W Scheithauer; C Zielinksi; H Ludwig
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases.

Authors:  Romuald Le Scodan; David Ali; Denise Stevens
Journal:  BMC Cancer       Date:  2010-11-17       Impact factor: 4.430

5.  Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors.

Authors:  Y Touitou; F Lévi; A Bogdan; M Benavides; F Bailleul; J L Misset
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 6.  Postmenopausal breast cancer. Drug therapy in the 1990s.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

7.  Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer.

Authors:  M Millward; M Lind; L Gumbrell; A Robinson; T Lennard; B Cantwell
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.

Authors:  D F Hayes; H Sekine; T Ohno; M Abe; K Keefe; D W Kufe
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 9.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

10.  Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.

Authors:  S-E Al-Batran; M Güntner; C Pauligk; M Scholz; R Chen; B Beiss; S Stopatschinskaja; W Lerbs; N Harbeck; E Jäger
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.